Eclipsebio is the exclusive license holder to patents covering key aspects of Ribo-Seq technology developed by inventors Weismann and Ingolia at the University of California, San Fransisco (UCSF)
SAN DIEGO, July 27, 2023 /PRNewswire/ -- Eclipsebio, a leading provider of innovative RNA analysis solutions, announces the launch of its proprietary eRibo Pro™ service, an all-inclusive offering to identify differential transcription and translation as well as ribosome positioning. The launch of eRibo Pro™ marks an important milestone in Eclipsebio's mission to accelerate the development of tomorrow’s key RNA genomics discoveries & medicines by providing researchers with tools to interrogate the complexity of RNA. Eclipsebio will unveil eRibo Pro™ at Hanson Wade’s 3rd mRNA-Based Therapeutics Summit, July 27th, 2023.
eRibo Pro™ is a service solution that streamlines ribosome profiling data collection, allowing researchers to offload sample processing, sequencing, and data analysis. The comprehensive service includes high resolution mapping of ribosome footprints and identification of differentially transcribed and translated genes with interactive reports that allow researchers to make data driven insights.
“The eRibo Pro service significantly accelerates development timelines and offers researchers a hassle-free experience by eliminating the need for extensive staff training and capital equipment.” said Eclipsebio CEO & co-founder Peter Chu, Ph.D. “With cost-effective pricing, eRibo Pro delivers exceptional value, making it an ideal choice for both small-scale studies and large-scale projects, providing researchers with unparalleled access to translation data.”
eRibo Pro™ incorporates exclusively licensed technology for Ribo-Seq developed by Drs. Jonathan Weissman and Nicholas Ingolia at UCSF. The underlying patents cover innovations related to methods for monitoring translation via ribosome profiling, covered under U.S. Patent Numbers 8,486,865, 9,284,547 and 9,677,068.
About Eclipsebio
Eclipsebio is a private biotechnology company headquartered in San Diego, developing first-in-class technologies to accelerate the development of tomorrow’s key RNA genomics discoveries and medicines. The company offers its end-to-end RNA genomics products as services and kits and also provides custom RNA genomics services for select partners. For more info, visit www.eclipsebio.com.
Contact
Media inquiries can be made to press@eclipsebio.com
Latest news
Eclipsebio Launches eMERGE™ Platform, a Cutting-Edge End-to-End Solution for the Characterization and Optimization of RNA-Based Therapeutic Products
Eclipse Bioinnovations, Inc. (Eclipsebio), the leading RNA genomics company developing and commercializing novel, data-driven technologies and analyses that interrogate RNA, today announced the launch of its proprietary eMERGE™ platform.
RNA UK 2024
Eclipsebio is proud to announce their sponsorship of RNA UK 2024, the premier event for bringing experts in RNA biology together to discuss the latest RNA discoveries.
Eclipsebio Launches eRibo Pro™, a Ribosome Profiling Service to Obtain RNA Translation Data
Eclipsebio, a leading provider of innovative RNA analysis solutions, announces the launch of its proprietary eRibo Pro™ service, an all-inclusive offering to identify differential transcription and translation as well as ribosome positioning. The launch of eRibo Pro™ marks an important milestone in Eclipsebio's mission to accelerate the development of tomorrow’s key RNA genomics discoveries & medicines by providing researchers with tools to interrogate the complexity of RNA.
Eclipsebio Launches eSHAPE™ Product Family to Provide RNA Structure Probing at AGBT 2023
Eclipse Bioinnovations (Eclipsebio),a leading RNA genomics company developing and commercializing novel, data-driven technologies that interrogate RNA, today announced the launch of its eSHAPE™ suite of technologies that enable exploration of RNA secondary structure from RNA samples. Details on the eSHAPE technology, how researchers can benefit from it, and the different products involved will be available at a networking event and a break table discussion at the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting being held February 6-9 in Hollywood, Florida.